Am J Transplant, Volume 18, Suppl 3 Archives - Page 132 of 211 - ATC Abstracts

2018 American Transplant Congress
An Early Look at the OPTN's New SLK Allocation Policy
A. Kucheryavaya,¹ R. Formica,² N. Turgeon,³ D. Stewart,¹ A. Wilk.¹
¹UNOS, Richmond; ²Yale School of Medicine, New Haven; ³Emory Univ Hosp, Atlanta.
Background: The new Simultaneous Liver-Kidney (SLK) allocation policy went into effect on 8/10/17. It established renal medical criteria for patients waiting for SLK transplants and…
2018 American Transplant Congress
Urine AngiotensinII Signature Proteins as Biomarkers of Fibrosis in Kidney Transplant Recipients
Z. Mohammed-Ali,¹ S. Reid,^1,3 T. Tokar,¹ A. Tavares,² P. Yip,¹ H. Cardinal,² Y. Li,¹ S. Kim,^1,3 I. Jurisica,^1,3 R. John,¹ A. Konvalinka.^1,3
¹University Health Network, Toronto, ON, Canada; ²Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada; ³University of Toronto, Toronto, ON, Canada.
AngiotensinII (AngII), the main effector of the renin-angiotensin system (RAS), causes kidney interstitial fibrosis/tubular atrophy (IFTA). However, there are presently no markers of AngII renal…
2018 American Transplant Congress
Peripheral Blood Immune Response-Related Gene Analysis for Evaluating the Development of Subclinical Antibody-Mediated Rejection
T. Yamamoto,¹ K. Iwasaki,² K. Murotani,³ A. Takeda,⁴ M. Tsujita,⁴ T. Hiramitsu,⁴ N. Goto,⁴ S. Narumi,⁴ Y. Watarai,⁴ K. Uchida,² T. Kobayashi.⁵
¹Xenotransplantation, University of Alabama at Birmingham, Birmingham, AL; ²Kidney Disease and Transplant Immunology, Aichi Medical University, Nagakute, Japan; ³Biostatistics, Aichi Medical University, Nagakute, Japan; ⁴Kidney Center, Nagoya Daini Red Cross Hospital, Nagoya, Japan; ⁵Renal Transplant Surgery, Aichi Medical University, Nagakute, Japan.
Background: Noninvasive methods for the early diagnosis of chronic antibody-mediated rejection (cAMR) are desired for patients with de novo (dn) donor-specific HLA antibody (DSA) because…
2018 American Transplant Congress
Isolation and Profiling of miRNAs from Formalin Fixed Paraffin Embedded Endomyocardial Tissues from Human Heart Transplant Recipients
R. Nog,^1,2 C. Gupta,^1,2 J. Fallon,^1,2 J. Panza,^1,2 N. Haque.²
¹Westchester Medical Center, Valhalla, NY; ²New York Medical College, Valhalla, NY.
Allograft rejection is a common complication post heart transplant (HTx) and can be confirmed by endomyocardial biopsy (EBx) only. There is however an increasing need…
2018 American Transplant Congress
Molecular Classifiers Can Outperform the Flawed Histologic “Gold Standard” on Which They Are Trained
J. Reeve, P. Halloran.
University of Alberta, Edmonton, Canada.
The histologic diagnosis of rejection in organ transplants is known to be an imperfect gold standard. Therefore, it might be assumed that molecular classifiers built…
2018 American Transplant Congress
Cardiac Grafts from Insulin Resistant Donors Trigger a Heightened Immune Response via Excessive Induction of Autophagy
S. Cai,¹ J. Miao,² A. Chandraker.¹
¹Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, MA; ²Division of Endocrinology, Boston Children's Hospital, Boston, MA.
Background Heart transplantation remains the treatment of choice for many patients with medically refractory heart failure. The use of organs from patients with insulin resistant…
2018 American Transplant Congress
A Pre-Transplant Blood-Based Lipid Signature for Prediction of Antibody-Mediated Rejection in Kidney Transplant Patients
G. Gupta, S. Bobba, D. Contaifer, P. Kimball, A. King, D. Kumar, M. Levy, J. Stern, D. Wijesinghe.
Virginia Commonwealth University, Richmond.
BACKGROUNDThere is a lack of biomarkers for pre-kidney transplant immune risk stratification to avoid over- or under-immunosuppression. Since the circulating lipidome is integrally involved in…
2018 American Transplant Congress
Comparison of Bortezomib in Addition to Rituximab Based Treatment of Acute Antibody Mediated Rejection in Kidney Transplantation
A. Mattiazzi,^1,2 J. Pagan,^1,2 A. Arunachalam,¹ I. De la Cruz Alcantara,¹ J. Revollo,² A. Centeno,² A. Valdes,^1,2 G. Guerra.^1,2
¹Nephrology & Hypertension, University of Miami, Miami, FL; ²Miami Transplant Institute, Jackson Memorial Hospital, Miami, FL.
Purpose:The optimal treatment strategy of acute antibody mediated rejection (AMR) in renal allograft recipients remains undefined. The aim of our study was to compare the…
2018 American Transplant Congress
The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis
S. Wan,^1,2 T. Ying,^1,2 K. Wyburn,^1,2 D. Roberts,^3,4 M. Wyld,^1,2 S. Chadban.^1,2
¹Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia; ²Sydney Medical School, University of Sydney, Sydney, Australia; ³Department of Renal Medicine, Canberra Hospital and Health Services, Canberra, Australia; ⁴Medical School, Australian National University, Canberra, Australia.
Introduction: Current treatment strategies for antibody-mediated rejection (AMR) in kidney transplantation are based on low quality data from a small number of controlled trials. Novel…
2018 American Transplant Congress
Immunologic Impact of Tocilizumab Treatment in Kidney Transplant Recipients with Allograft Inflammation
J. Leung, S. Chandran, F. Vincenti, Q. Tang.
UCSF, San Francisco.
Background: Proinflammatory cytokine IL-6 increases effector/memory T-cells, induces Th17 cells and prevents the induction of Tregs. IL-6 expression in kidney biopsies is elevated during acute…